Creative Medical Technology Holdings (OTCMKTS:CELZ) Launches MyeloCelz™: What’s The Buzz?

Commercial stage biotechnology company specialising in regenerative stem cell technology, Creative Medical Technology Holdings (OTCMKTS:CELZ) on 20th July announced launch of its second Regenerative Immunology product, MyeloCelz.  

The firm’s ImmCelz product harnesses T cells and B cells for inducing activation of own stem cells and healing. On the other hand, MyeloCelzuses innate immune system, especially cells of monocyte/macrophage lineage. 

Thomas Ichim, Ph.D, Chief Scientific Officer, and Co-Founder said that immunotherapy is the future of medicine and has already saved thousands of lives in oncology. Ichim added that it is a first-in-class therapeutic direction leveraging amplification as well as and memory of the immune system for restoring body function.

Dr.Courtney Bartlett, Director of Clinical Development, said that the unique thing about the products is that they are personalised and also increase effectiveness as they body’s own cells know best how to react.

Dr.Camillo Ricordi said that it is astonishing to see innovation and productivity of the team assembled by Ichim and is a paradigm shift product covered by a comprehensive patent applications in cell therapy.

Timothy Warbington, President and CEO of the Company, said that the team has collaboratively worked and the addition of MyeloCelz toits Regenerative Immunotherapy portfolio, including ImmCelzas well as multiple patent filings for treating specific indications. “The unique thing about MyeloCelz™, like ImmCelz®, is that the cellular product is personalized and the patient is receiving their own cells back into themselves.  This not only significantly increases the safety of the procedure, but also conceptually may increase efficacy because the body’s own cells know best how to interact with the body.” Said Dr. Courtney Bartlett, Director of Clinical Development.